RTP Mobile Logo

In these one-on-one interviews with leading investigators, the faculty discuss the latest scientific developments in gynecologic cancers. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.
 

Subscribe to audio
and email programs »

RTP offers a variety of complimentary CME/CNE activities and series for physicians, nurses and other practicing healthcare professionals. Click the button on the right to subscribe to email and audio programs or to update your subscription information.

Interview with Robert L Coleman, MD

Track 1: Surgery versus neoadjuvant systemic therapy in the up-front management of ovarian cancer (OC)
Track 2: Personalized surgery for patients with advanced OC
Track 3: Goals of neoadjuvant chemotherapy in primary OC
Track 4: Ongoing trials evaluating neoadjuvant PARP inhibitor-based regimens for OC
Track 5: Second opinions for patients considering chemotherapy versus surgery as initial treatment for advanced OC
Track 6: Predictors of response to bevacizumab in patients with OC
Track 7: GOG 0213: Results of a Phase III trial of carboplatin/paclitaxel alone or in combination with bevacizumab → bevacizumab and secondary debulking surgery in platinum-sensitive recurrent OC
Track 8: Secondary cytoreductive surgery in OC
Track 9: Current role of bevacizumab in OC
Track 10: Activity of PARP inhibitors alone or in combination with chemotherapy for patients with advanced OC and a germline BRCA 1/2 mutation
Track 11: ARIEL2: Results of a Phase II trial to prospectively identify patients with platinum-sensitive OC likely to respond to the PARP inhibitor rucaparib using tumor genetic analysis
Track 12: Gastrointestinal (GI) toxicity and anemia with olaparib in OC
Track 13: Case discussion: A 37-year-old woman develops metastatic cervical cancer 2 years after initial diagnosis and receives cisplatin/paclitaxel/bevacizumab on the GOG 0240 trial
Track 14: Treatment options for patients with metastatic cervical cancer
Track 15: Effect of prior radiation therapy on ability to tolerate further treatment for metastatic cervical cancer
Track 16: Management of bevacizumab-associated side effects in patients with metastatic cervical cancer
Track 17: Case discussion: A 71-year-old woman with Grade II endometrial cancer obtains a near complete response with paclitaxel/carboplatin/dasatinib on a clinical trial
Track 18: Case discussion: A 60-year-old woman with recurrent platinum-sensitive OC is found to harbor a BRCA1 mutation and responds to olaparib

Interview with Bradley J Monk, MD

Track 19: Therapeutic options for patients with relapsed platinum-sensitive OC
Track 20: Perspective on intraperitoneal chemotherapy in OC
Track 21: Viewpoint on the results of the GOG 0213 trial: Bevacizumab in platinum-sensitive recurrent OC
Track 22: Clinical experience with and management of bevacizumab-associated hypertension and GI perforation
Track 23: Use of bevacizumab maintenance therapy for patients with OC
Track 24: BRCA testing in epithelial OC
Track 25: Activity of the PARP inhibitor olaparib in metastatic OC
Track 26: Practical issues in prescribing olaparib for OC
Track 27: Anemia and risk of second cancers with olaparib
Track 28: Immunotherapy including checkpoint inhibitors in advanced OC and cervical cancer
Track 29: Development of the antibody-drug conjugate mirvetuximab soravtansine (IMGN853)
Track 30: Activity of mirvetuximab soravtansine in advanced OC and endometrial cancer
Track 31: Unique side-effect profile of mirvetuximab soravtansine
Track 32: Activity of initial bevacizumab-based therapy for Stage III/IV recurrent endometrial cancer
 
FACULTY:
 
Robert L Coleman, MD
Professor and Deputy Chairman
Vice Chair, Clinical Research
Ann Rife Cox Chair in
Gynecology
Department of Gynecologic
Oncology and Reproductive
Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
 
Bradley J Monk, MD
Professor and Director, Division
of Gynecologic Oncology
Vice Chair, Department of
Obstetrics and Gynecology
University of Arizona Cancer
Center and Creighton University
School of Medicine at
Dignity Health
St Joseph’s Hospital and
Medical Center
Phoenix, Arizona
 
MODERATOR:
 
Neil Love, MD
Research To Practice
Miami, Florida